MapLight Therapeutics, Inc. 8-K

What Happened

• On June 18, 2026, MapLight Therapeutics, Inc. announced the immediate separation of its Chief Financial Officer, Vishwas Setia, following a review of a human resources violation. The company said the separation was unrelated to its financial or operating results, internal controls, clinical programs, or reporting practices.
• The board appointed Jonathan Gillis, the company’s Chief Administrative and Accounting Officer, as interim Chief Financial Officer and interim principal financial officer effective June 18, 2026. Mr. Gillis will continue as the company’s principal accounting officer.

Key Details

• Separation date: June 18, 2026 (immediate).
• No severance payment is owed to Mr. Setia; however, the Separation Agreement provides a release of claims and up to three months of continued health coverage under COBRA.
• The company stated the separation is wholly unrelated to financial results, internal controls, clinical programs, or reporting practices.
• MapLight intends to file the full Separation Agreement as an exhibit to its Form 10-Q for the quarter ending June 30, 2026.

Why It Matters

• Leadership change in the finance function can affect investor confidence and operational continuity; appointing an internal executive (Mr. Gillis) as interim CFO reduces transition risk.
• The company’s explicit statement that the separation is unrelated to financial reporting or internal controls is intended to reassure investors about the integrity of financial statements and ongoing reporting.
• The limited cash impact disclosed (no severance; COBRA coverage for up to three months) suggests minimal near-term financial cost from the departure.